Therapy Directory

Trastuzumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Trastuzumab as a study intervention. Browse Trastuzumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

678

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Solid Tumor, Adult
Interventions: FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion; Drug · Combination Product
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions: FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab; Drug · Combination Product
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more

Conditions: Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST, Ovarian Cancer
Interventions: HER-2 vaccine, Extension HER-2 vaccine trial at OBD; Biological
Lead sponsor: Robert Wesolowski; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer
Interventions: Ruxolitinib, Trastuzumab; Drug
Lead sponsor: Dawn L. Hershman; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: New York, New York

Conditions: Locally Advanced Breast Cancer
Interventions: Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Pegfilgrastim, Paclitaxel, Doxorubicin, Cyclophosphamide; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: New York, New York

Conditions: HER2 Positive Breast Cancer
Interventions: tucatinib, capecitabine, trastuzumab, placebo; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 66 more

Conditions: Breast Cancer Stage IV
Interventions: Tucatinib; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Clackamas, Oregon • Newberg, Oregon • Portland, Oregon

Conditions: Breast Cancer
Interventions: Eribulin Mesylate; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 26
States / cities: Denver, Colorado • Davie, Florida • Jacksonville, Florida + 22 more

Conditions: Endometrial Cancer
Interventions: Carboplatin/Paclitaxel, Trastuzumab; Drug
Lead sponsor: Yale University; Other
Eligibility: Female only
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • Concord, California + 16 more

Conditions: Neoplasms, Breast
Interventions: lapatinib, paclitaxel, trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2019
U.S. locations: 14
States / cities: Roswell, Georgia • Joliet, Illinois • Detroit, Michigan + 10 more

Conditions: Breast Cancer, Breast Cancer, Male, Breast Cancer Female, HER2-positive Breast Cancer
Interventions: Interferon-gamma (IFN-γ), Paclitaxel, Trastuzumab, Pertuzumab, Post Therapy Surgery; Biological · Drug · Other + 1 more
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

About this Trastuzumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Trastuzumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Trastuzumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Trastuzumab clinical trials

Filter and sort this therapy

Live official records

Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer

About this Trastuzumab clinical trials directory page